Andrew Parece and Urs Wiedemann published an article in the April issue of Pharmaceutical Executive. The authors discuss outcomes-based, risk-sharing agreements as one approach to change the dialogue between manufacturers and payers, from price to value. To read the article, click the link below.
Analytics for clinical development strategy: Tools and opportunities
In the final part of the series, CRA’s Dr. Nick Davies presents an overview of current and emerging analytical tools and explores the opportunities for their...